Discover and read the best of Twitter Threads about #BreastCancer
Most recents (24)
@TumorBoardTues @drsarahsam 1/24 #TumorBoardTuesday #BreastCancer #OncTwitter
54yo 👩🏻 post-menopausal
HTN
hypothyroidism
FH: aunt with late-onset BC
Germline genetic testing: negative
🔪Dec ‘10 Left lumpectomy + SLNB:
left IDC G2
ER 95%
PgR 10%
HER2-neg (IHC 1+)
Ki67 35%
stage pT2 (25 mm) pN0
Oncotype 32
54yo 👩🏻 post-menopausal
HTN
hypothyroidism
FH: aunt with late-onset BC
Germline genetic testing: negative
🔪Dec ‘10 Left lumpectomy + SLNB:
left IDC G2
ER 95%
PgR 10%
HER2-neg (IHC 1+)
Ki67 35%
stage pT2 (25 mm) pN0
Oncotype 32
@TumorBoardTues @drsarahsam 2/24 #TumorBoardTuesday #BCSM
☢️Jan ‘11: TC x 4 ➡️ XRT
Treatment well tolerated, apart from alopecia, G2 fatigue
Summer ‘11 – started letrozole
🔀 Fall ‘11 – switch to exemestane due to G3 arthralgias ➡️ improvement of symptoms
2016 completed 5 years of Aromatase Inhibitor
☢️Jan ‘11: TC x 4 ➡️ XRT
Treatment well tolerated, apart from alopecia, G2 fatigue
Summer ‘11 – started letrozole
🔀 Fall ‘11 – switch to exemestane due to G3 arthralgias ➡️ improvement of symptoms
2016 completed 5 years of Aromatase Inhibitor
@TumorBoardTues @drsarahsam 3/24 #TumorBoardTuesday #BCSM
Apr ‘21 – Mild abdo discomfort
🩻CT CAP scan:
liver: 5 lesions, max 15 mm
bone: spine & ribs
enlarged mediastinal lymph nodes
🩸: G1 anemia, normal LFTs, no other abnormality
🔬US-guided liver biopsy:
IDC, grade 2, ER 90%, PR 0%, HER2-0, Ki67 25%
Apr ‘21 – Mild abdo discomfort
🩻CT CAP scan:
liver: 5 lesions, max 15 mm
bone: spine & ribs
enlarged mediastinal lymph nodes
🩸: G1 anemia, normal LFTs, no other abnormality
🔬US-guided liver biopsy:
IDC, grade 2, ER 90%, PR 0%, HER2-0, Ki67 25%
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 2/5 #TumorBoardTuesday
Thurs Case🎀
✅Biomarker - sq cell #LC, chemoIO is the SOC
✅Pembro, cemi, ipi/nivo approved in 1L squamous cell lung cancer—must be paired with chemo if PD-L1 TPS < 50%
✅ irAEs can be very serious- early, multi-D mgmt is 🗝️
Thurs Case🎀
✅Biomarker - sq cell #LC, chemoIO is the SOC
✅Pembro, cemi, ipi/nivo approved in 1L squamous cell lung cancer—must be paired with chemo if PD-L1 TPS < 50%
✅ irAEs can be very serious- early, multi-D mgmt is 🗝️
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 3/5 #TumorBoardTuesday
Thurs Case🎀
📽️TBT video wrap up:
IO has fundamentally changed 🫁 cancer tx.
Choosing the right strategy in squamous cell lung ca largely based on PD-L1 status; we’re hoping for more, & better, biomarkers in the future.
Thurs Case🎀
📽️TBT video wrap up:
IO has fundamentally changed 🫁 cancer tx.
Choosing the right strategy in squamous cell lung ca largely based on PD-L1 status; we’re hoping for more, & better, biomarkers in the future.
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 4/5 #TumorBoardTuesday
Thurs Case🎀
📷TBT in an image:
Check out this algo to help select IO vs chemoIO strat in #squamouscell #lcsm lung cancer 1L setting.
No head-to-head 👊data to define clear winner, but pembro, cemiplimab, and ipi/nivo approved based on OS benefit.
Thurs Case🎀
📷TBT in an image:
Check out this algo to help select IO vs chemoIO strat in #squamouscell #lcsm lung cancer 1L setting.
No head-to-head 👊data to define clear winner, but pembro, cemiplimab, and ipi/nivo approved based on OS benefit.
1/22 #TumorBoardTuesday #OncTwitter
60yo 👩🏻
ER+/PR-/HER2 low met #BreastCancer
Since 2016: 3 lines of endocrine therapy including AI+CDK 4/6 inhibitor ➡️ Fulvestrant ➡️ Everolimus+exemestane
No actionable mutation
🤨 What would be your first chemotherapy choice:
60yo 👩🏻
ER+/PR-/HER2 low met #BreastCancer
Since 2016: 3 lines of endocrine therapy including AI+CDK 4/6 inhibitor ➡️ Fulvestrant ➡️ Everolimus+exemestane
No actionable mutation
🤨 What would be your first chemotherapy choice:
2/22 #TumorBoardTuesday @MPishvaian @JohnEbbenMDPhD #BreastCancer #BCSM
2021*: Started on capecitabine for 8 months until POD
2022: Switched to paclitaxel for 5 months ➡️ POD in the liver and pleura
🤨 What would be your next step?
2021*: Started on capecitabine for 8 months until POD
2022: Switched to paclitaxel for 5 months ➡️ POD in the liver and pleura
🤨 What would be your next step?
3/22 #TumorBoardTuesday
👩🏻🏫Mini tweetorial 1
📌What is HER2-low?
🔸Traditionally HER2-positive and HER2-negative were separate entities
🔸NOW, HER2-low is a separate entity 👉🏽 1+ or 2+ on IHC and ISH negative‼️
📚@PTarantinoMD @curijoey @stolaney1 aacrjournals.org/cancerdiscover…
👩🏻🏫Mini tweetorial 1
📌What is HER2-low?
🔸Traditionally HER2-positive and HER2-negative were separate entities
🔸NOW, HER2-low is a separate entity 👉🏽 1+ or 2+ on IHC and ISH negative‼️
📚@PTarantinoMD @curijoey @stolaney1 aacrjournals.org/cancerdiscover…
“Women are under such pressure to look a certain way that they must undergo this pain after a traumatic surgery. That’s why I decided to make crocheted or knitted prostheses," says
Jayashree Ratan.
#HeroesOfHumanity #WorldCancerDay #Kindness #WomenForWomen #Healthcare
Jayashree Ratan.
#HeroesOfHumanity #WorldCancerDay #Kindness #WomenForWomen #Healthcare
Jayashree Ratan creates crocheted #prostheses for #breastcancer survivors.
Made from 100 per cent mercerised cotton yarn, these prostheses are soft on the skin and do not cause allergies.
Made from 100 per cent mercerised cotton yarn, these prostheses are soft on the skin and do not cause allergies.
While each can be used for nearly two years, these washable hands fit well into the mastectomy bra.
“We never knew we would touch so many lives by spending just a few hours on each product. That is our biggest reward,” says Jayashree.
“We never knew we would touch so many lives by spending just a few hours on each product. That is our biggest reward,” says Jayashree.
Today is #WorldCancerDay
Few diseases reflect global inequities as starkly as #BreastCancer and #CervicalCancer.
Nearly 8⃣0⃣% of deaths from breast and cervical cancer occur in low- and middle-income countries.
#CloseTheCareGap in #cancer ⬇️
Few diseases reflect global inequities as starkly as #BreastCancer and #CervicalCancer.
Nearly 8⃣0⃣% of deaths from breast and cervical cancer occur in low- and middle-income countries.
#CloseTheCareGap in #cancer ⬇️
On #WorldCancerDay, here are some ways to reduce ↘️ your #cancer risk:
🚭 Don't use tobacco
🏊♂️ Exercise regularly
🍅 Eat healthy foods
☀️ Avoid strong sunlight for prolonged periods
🥃 Drink less alcohol
📌 bit.ly/2Bh7xnG
🚭 Don't use tobacco
🏊♂️ Exercise regularly
🍅 Eat healthy foods
☀️ Avoid strong sunlight for prolonged periods
🥃 Drink less alcohol
📌 bit.ly/2Bh7xnG
Today is #WorldCancerDay
These are the 5⃣ most common types of #cancer:
🔸 breast
🔸 lung
🔸 colorectal
🔸 stomach
🔸 prostate
📌 bit.ly/2Bh7xnG
These are the 5⃣ most common types of #cancer:
🔸 breast
🔸 lung
🔸 colorectal
🔸 stomach
🔸 prostate
📌 bit.ly/2Bh7xnG
We have insights! Learn about how insurance companies have gamed the medical coding process to deny #breastcancer patients access to modern #reconstruction treatments @DavidArmstrongX @propublica @PatrickMRucker @mayatmiller
This petition explains:
change.org/p/save-access-…
This petition explains:
change.org/p/save-access-…
drpotter.com/advocacy/ and what is a flap surgery drpotter.com/diep-flap-reco…
Breast Conservation | The importance of self breast examination!
“Self berast examination allows you to evaluate your own breast, it teaches you to examine your breast, understand the lumps and bumps in your breasts.”
@TataMemorial | @CancerGridIndia | @nitaSnair
#Navya
“Self berast examination allows you to evaluate your own breast, it teaches you to examine your breast, understand the lumps and bumps in your breasts.”
@TataMemorial | @CancerGridIndia | @nitaSnair
#Navya
Listen to Dr. Nita S Nair, Surgical oncologist and Professor in breast oncology at the Tata Memorial Centre, Mumbai. give us valuable insights into Breast Conservation.
#Cancer #TMCNCGNavyaWay #BreastCancer #BreastConservation
#Cancer #TMCNCGNavyaWay #BreastCancer #BreastConservation
TMC NCG Navya ensures that all cancer patients can afford treatment recommendations from expert oncologists through our strong alliances with experts, nonprofits, and industry.
#CancerCare #HealthIsWealth #BreastExamination
#CancerCare #HealthIsWealth #BreastExamination
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD 1/17 #TumorBoardTuesday #BreastCancer #OncTwitter @JasmineSukumar @DrGattiMays
👩🏽 65 yo post-menopausal
🚫comorbidities
🔺Triple-neg MBC, germline BRCA1 mut+, PD-L1 neg
👉On carbo/gem for 6 cycles
🩻NOW: Scans show progression in liver
🤨What 2L treatment do you recommend?
👩🏽 65 yo post-menopausal
🚫comorbidities
🔺Triple-neg MBC, germline BRCA1 mut+, PD-L1 neg
👉On carbo/gem for 6 cycles
🩻NOW: Scans show progression in liver
🤨What 2L treatment do you recommend?
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays 2/17 #TumorBoardTuesday #bcsm
🤨 Poll: What percent of all people diagnosed with #BreastCancer carry a germline BRCA 1 and/or 2 mutation?
🤔Are there features that might make you more likely to suspect a patient is a mutation carrier?
@StoverLab @sardesai_sagar @OncoAlert
🤨 Poll: What percent of all people diagnosed with #BreastCancer carry a germline BRCA 1 and/or 2 mutation?
🤔Are there features that might make you more likely to suspect a patient is a mutation carrier?
@StoverLab @sardesai_sagar @OncoAlert
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert 3/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 1👩🏻🏫
📌BRCA1/2 mutation
🔸Repair double-stranded breaks thru HRR
🔸Unable to fix 🧬 when damaged ➡️ add’l muts ➡️ cancer
🔸~5% of #BreastCancer;⬆️w/ TNBC
🔸Assoc w/ 40-65% of BC dx in 🚺, ≤ 9% in 🚹
📚science.org/doi/10.1126/sc…
👩🏽🏫Mini tweetorial 1👩🏻🏫
📌BRCA1/2 mutation
🔸Repair double-stranded breaks thru HRR
🔸Unable to fix 🧬 when damaged ➡️ add’l muts ➡️ cancer
🔸~5% of #BreastCancer;⬆️w/ TNBC
🔸Assoc w/ 40-65% of BC dx in 🚺, ≤ 9% in 🚹
📚science.org/doi/10.1126/sc…
For being the best #IPS probationer, Dr Darpan Ahluwalia was awarded the Prime Minister’s Baton and Home Ministry’s (MHA) revolver during the valedictory ceremony at the #NationalPoliceAcademy.
@AhluwaliaDarpan
@AhluwaliaDarpan
An #MBBS degree holder from Government Medical College in Patiala, Ahluwalia also bagged the Vice President of India's trophy for exemplary conduct and Martyr K S Vyas trophy for internal security, public order and field craft and tactics.
On a mission to serve the public, Dr Ahluwalia also organises #breastcancer screening camps in #Punjab through the NGO Pink Link Campaign.
Resources for those facing #breastcancer that I've personally used and found AMAZING. @ThanksCancer
A 🧵with links. Please share yours below.
A 🧵with links. Please share yours below.
Sharsheret - for people of all faiths to find financial and emotional support. I was matched with a social worker who sent a care pack and matched me with a mentor sharsheret.org
Gilda's Club - I was incredibly overwhelmed at diagnosis but soon landed at my local chapter. Since I've utilized creative writing and art workshops, survivorship support, and even a free turkey at Thanksgiving gildasclubmadison.org
I've missed out on a lot of events this year due to #breastcancer, which means I've missed opportunities to engage with readers about my new book, #TheFacemaker. So, let me take a moment to tell you more about this book, which took me five years to research and write.👇 /1
From the moment the first machine gun rang out over the Western Front, one thing was clear: Europe’s military technology had wildly surpassed its medical capabilities. Bodies were battered, gouged, hacked, and gassed.
Never before had the world faced such slaughter. /2
Never before had the world faced such slaughter. /2
Stretcher-bearers could rarely step onto a battlefield without becoming a target. Their mortality rates were extraordinarily high. When Private W. Lugg picked up an injured man, it took him ten hours to travel 400 meters. Wheeled carts were mostly useless on blasted terrain. /3
We are thrilled to share #Starfysh ⭐️ an auxiliary deep generative model for multi-modal analysis and integration of spatial transcriptomic (ST) datasets and histology images, and its application to heterogeneous #breastcancer tumors! 😃 tinyurl.com/hffdhvx7 1/
Incredibly fortunate to have a passionate, collaborative & talented team that didn't slow down with all the challenges of the past few years 🙏: @SiyuHe7 @YinuoJin6, @AchilleNazaret @shi_lingting and a fruitful and ongoing collaboration with @GeorgePlitas and Sasha Rudensky. 2/
Using ST, we wanted to find out if our previously observed continuous phenotypic expansion of intratumoral immune states (doi.org/10.1016/j.cell…) could be explained by the #spatialdynamics of immune cells and exposure to different environmental signals and nutrient supply? 🧐 3/
One of the most laughable things I’ve realized is people hosting Race for the Cure runs for #breastcancer but serving sugar laden donuts & cookies after. If they really want to help w/ cancer they should promote a lifestyle of zero sugar & fasting instead….but that’s not fun.
Another one is #Alzheimer fundraisers, again w/ alcoholic drinks & sugary food at the events, which totally contribute to dementia & poor brain cognition. But people want a photo dump of them “working” for a cause even if their efforts contradict good health. They need a party.
Because it’s not “really” about health, for if it were, they’d do their own research to see the food & drinks they’re serving actually contribute to these diseases. It’s about people being conditioned by Pharma & allopathic medicine & being clueless about how to heal from them.
#WomensHealthcare needs serious attention, specifically patient comfort. There are procedures that the patient is given no anesthesia for that are down right medieval. For example, lets visit something called an endometrial biopsy, a procedure that detects uterine cancer… 1
1You will be asked to undress fully or from the waist down and put on a hospital gown.
2You will be told to empty your bladder before the procedure.
3You will lie on an exam table, with your feet and legs supported as for a pelvic exam…
2You will be told to empty your bladder before the procedure.
3You will lie on an exam table, with your feet and legs supported as for a pelvic exam…
4. Your healthcare provider will insert an instrument called a speculum into your vagina to spread the walls of the vagina apart to view the cervix.
5. Your provider will clean your cervix with an antiseptic solution….
5. Your provider will clean your cervix with an antiseptic solution….
🧵
"Traición de la naturaleza"
(La lucha contra el cáncer de mama).
Un día, la naturaleza llevó la lucha por la supervivencia a los senos de la mujer. Atentó contra uno de los símbolos más sagrados que posee el ser humano, y golpeó, con saña, a nuestras madres.
"Traición de la naturaleza"
(La lucha contra el cáncer de mama).
Un día, la naturaleza llevó la lucha por la supervivencia a los senos de la mujer. Atentó contra uno de los símbolos más sagrados que posee el ser humano, y golpeó, con saña, a nuestras madres.
Sin herramientas ni fármacos, otra vez la piedra del conocimiento debió tallarse rudimentariamente por siglos, para equilibrar la balanza. Indefenso, el hombre tuvo que cortar, y echó mano de los vestigios ancestrales de lo que hoy es la cirugía. Cortó, a destajo, cuerpo y alma.
La mastectomía apareció en el siglo II, d.C. siempre seguida del fuego ardiente que cauterizaba los vasos sangrantes; obvio no sería suficiente. 1200 años después empezaron a retirar los ganglios linfáticos axilares, tras entender que tendían a infestarse por el cáncer.
@TumorBoardTues @DrSGraff @CharlesMilrod 1/18 #TumorBoardTuesday #OncTwitter
44 yo👩🏾
Stage 1 triple neg #BreastCancer #TNBC
✂️right lumpectomy
adj ACx4
radiation ☢️
8⃣🗓️months later
New R breast mass, ⬆️fatigue x3 mos
🩻CT many small 🫁 nodules & 4cm liver mass
🔬Breast & Liver ➡️ breast ca ER0% PR0% HER2 1+
Now?
44 yo👩🏾
Stage 1 triple neg #BreastCancer #TNBC
✂️right lumpectomy
adj ACx4
radiation ☢️
8⃣🗓️months later
New R breast mass, ⬆️fatigue x3 mos
🩻CT many small 🫁 nodules & 4cm liver mass
🔬Breast & Liver ➡️ breast ca ER0% PR0% HER2 1+
Now?
@TumorBoardTues @DrSGraff @CharlesMilrod 2/18 #TumorBoardTuesday
Closer look at the biopsies:
🔬Breast: Invasive Ductal Carcinoma w/dense lymphocytic infiltrate, G3, ER 0% PR 0% HER2 1+
🔬Liver: met carcinoma c/w breast primary, ER staining absent
❓What additional testing?
🤨Would it differ with ER+ #BreastCancer?
Closer look at the biopsies:
🔬Breast: Invasive Ductal Carcinoma w/dense lymphocytic infiltrate, G3, ER 0% PR 0% HER2 1+
🔬Liver: met carcinoma c/w breast primary, ER staining absent
❓What additional testing?
🤨Would it differ with ER+ #BreastCancer?
@TumorBoardTues @DrSGraff @CharlesMilrod 3/18 #TumorBoardTuesday #BreastCancer
📌For metastatic #TNBC
📍Germline BRCA1/2 (gBRCApv) and PD-L1 are 🔑 in early decision making📍
🤔What if she were 3L or beyond?
❓What factors–clinical, genomic–impact decisions?
📌For metastatic #TNBC
📍Germline BRCA1/2 (gBRCApv) and PD-L1 are 🔑 in early decision making📍
🤔What if she were 3L or beyond?
❓What factors–clinical, genomic–impact decisions?
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 2/4 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?
📚We captured @drteplinsky’s discussion in this moment: twitter.com/i/events/15831…
Thurs Case🎀
Take🏠messages:
#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?
📚We captured @drteplinsky’s discussion in this moment: twitter.com/i/events/15831…
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 3/4 #TumorBoardTuesday
Thursday Case🎀
📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!
We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd?
Thursday Case🎀
📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!
We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd?
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates 4/4 #TumorBoardTuesday
Thurs Case🎀
🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?
➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
Thurs Case🎀
🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?
➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
@TumorBoardTues 1/15 #TumorBoardTuesday #BreastCancer #OncTwitter
59yo 👩🏽
palpable left breast mass
Dx: clinical prognostic stage IIB node positive (cT2N1) ER+/PR-/HER2+ poorly differentiated invasive ductal carcinoma.
She’s referred for neoadjuvant chemotx.
🤨What treatment do you offer her?
59yo 👩🏽
palpable left breast mass
Dx: clinical prognostic stage IIB node positive (cT2N1) ER+/PR-/HER2+ poorly differentiated invasive ductal carcinoma.
She’s referred for neoadjuvant chemotx.
🤨What treatment do you offer her?
@TumorBoardTues 2/15 #TumorBoardTuesday #BCSM
👩🏽 receives neoadjuvant chemotherapy with TCHP.
👩🏽 undergoes left mastectomy & sentinel lymph node biopsy & is found to have 12 mm of residual disease in breast.
No residual disease in the lymph nodes.
🤨 What adjuvant treatment do you recommend?
👩🏽 receives neoadjuvant chemotherapy with TCHP.
👩🏽 undergoes left mastectomy & sentinel lymph node biopsy & is found to have 12 mm of residual disease in breast.
No residual disease in the lymph nodes.
🤨 What adjuvant treatment do you recommend?
@TumorBoardTues 3/15 #TumorBoardTuesday
👩🏻🏫Mini tweetorial 1
✨KATHERINE Trial✨
🔸randomized open-label
🔸1486 🚺 with residual invasive HER2-positive early #BreastCancer after neoadjuvant taxane-containing chemotx +/- anthracyclines & trastuzumab
📚von Minckwitz @NEJM pubmed.ncbi.nlm.nih.gov/30516102
👩🏻🏫Mini tweetorial 1
✨KATHERINE Trial✨
🔸randomized open-label
🔸1486 🚺 with residual invasive HER2-positive early #BreastCancer after neoadjuvant taxane-containing chemotx +/- anthracyclines & trastuzumab
📚von Minckwitz @NEJM pubmed.ncbi.nlm.nih.gov/30516102
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 2/4 #TumorBoardTuesday
Thurs Case🎀
Take🏠
#EGFRm #NSCLC:
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation
📚We captured @n8pennell’s discussion:
twitter.com/i/events/15780…
Thurs Case🎀
Take🏠
#EGFRm #NSCLC:
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation
📚We captured @n8pennell’s discussion:
twitter.com/i/events/15780…
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 3/4 #TumorBoardTuesday
Thursday Case🎀
📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future!
Thursday Case🎀
📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future!
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic @esinghimd @nihardesai7 @NicoGagelmann @drteplinsky @jacobadashek 4/4 #TumorBoardTuesday
Thurs Case🎀
🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!
➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
Thurs Case🎀
🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!
➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
#breastCancerAwarenessMonth ramblings: I've been thinking about the words #fighter/#warrior/etc for #cancer patients recently. These thoughts have to go somewhere so here they are.
1/12
1/12
I'm one of the people these words apply to. Or they don't, idk.
If you don't know, I was diagnosed with #breastCancer in the spring of 2020, right on time for the first wave of the corona virus hitting my home.
It was a horrible time and it still often enough is.
2/
If you don't know, I was diagnosed with #breastCancer in the spring of 2020, right on time for the first wave of the corona virus hitting my home.
It was a horrible time and it still often enough is.
2/
I've used the fighter imagery, the hashtags #fightLikeAGirl and #strongAF and I have a bracelet that says "warrior" gifted to me by my sis for the first post-C Christmas that makes me ridiculously proud. Yet I know the flaws in that metaphor.
3/
3/
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 2/ #TumorBoardTuesday
Thurs Case🎀
Take🏠messages :
PIK3CA mutations in ER+ #mBC
✅PIK3CA mut are common- 20-30% of all #BreastCancer & 40%+ of ER+ #mBC
✅PIK3CAm are present in founder clones!
📚We captured as much of the discussion as we could:
Pt 1 twitter.com/i/events/15719…
Thurs Case🎀
Take🏠messages :
PIK3CA mutations in ER+ #mBC
✅PIK3CA mut are common- 20-30% of all #BreastCancer & 40%+ of ER+ #mBC
✅PIK3CAm are present in founder clones!
📚We captured as much of the discussion as we could:
Pt 1 twitter.com/i/events/15719…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 3/5 #TumorBoardTuesday
Thursday Case🎀
Take🏠messages (Part 2):
✅Alpelisib is a PIK3CA inhib= 5.3 mo ⬆️in PFS
✅Side effect mgmt is key- esp. 💩diarrhea,
🍦hyperglycemia
✅Personalized medicine needs personalized side effect mgmt
Part 2 of our convo twitter.com/i/events/15729…
Thursday Case🎀
Take🏠messages (Part 2):
✅Alpelisib is a PIK3CA inhib= 5.3 mo ⬆️in PFS
✅Side effect mgmt is key- esp. 💩diarrhea,
🍦hyperglycemia
✅Personalized medicine needs personalized side effect mgmt
Part 2 of our convo twitter.com/i/events/15729…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 4/5 #TumorBoardTuesday
📷 TBT in an image: Take a look at how PIK3CA inhibitors can be clinically deployed, key side effects to watch out for, and the data that supports their use.
👀Look for more developments in this space and even more, highly specific inhibitors to come.
📷 TBT in an image: Take a look at how PIK3CA inhibitors can be clinically deployed, key side effects to watch out for, and the data that supports their use.
👀Look for more developments in this space and even more, highly specific inhibitors to come.
@TumorBoardTues 1/17 #TumorBoardTuesday #bcsm
CASE: 55 yo post-menopausal 👩🏽
🚫comorbidities
HR+/HER2- MBC
🦴metastases, on letrozole+palbociclib 2 yrs
🩻Scans: progression in liver
🔬Liver biopsy: ER 90% PR 90% HER2- (IHC 1+)
Tissue NGS➡️ESR1 & PIK3CA mutation
🤨What 2L tx do you recommend?
CASE: 55 yo post-menopausal 👩🏽
🚫comorbidities
HR+/HER2- MBC
🦴metastases, on letrozole+palbociclib 2 yrs
🩻Scans: progression in liver
🔬Liver biopsy: ER 90% PR 90% HER2- (IHC 1+)
Tissue NGS➡️ESR1 & PIK3CA mutation
🤨What 2L tx do you recommend?
@TumorBoardTues 2/17 #TumorBoardTuesday #BCSM #OncTwitter
🤨 What is the prevalence of PIK3CA activating mutations in metastatic HR+/HER2- breast cancer?
@Dr_RShatsky @PTarantinoMD @hoperugo @NicoleKuderer @StoverLab @CarmenCalfa @sardesai_sagar @stolaney1 @OncoAlert
🤨 What is the prevalence of PIK3CA activating mutations in metastatic HR+/HER2- breast cancer?
@Dr_RShatsky @PTarantinoMD @hoperugo @NicoleKuderer @StoverLab @CarmenCalfa @sardesai_sagar @stolaney1 @OncoAlert
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @hoperugo @NicoleKuderer @StoverLab @CarmenCalfa @sardesai_sagar @stolaney1 @OncoAlert 3/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 1👩🏻🏫
🔸⬆️PI3K/Akt/mTOR pathway➡️cell proliferation, growth & survival
🔸Class I PIK3 proteins have catalytic subunit (p110)
🔸p110 contains 4 isoforms: α, β, γ, δ
🔸p110α mut (PIK3CA encoded)➡️ resistance to ET
📚pubmed.ncbi.nlm.nih.gov/31828441/
👩🏽🏫Mini tweetorial 1👩🏻🏫
🔸⬆️PI3K/Akt/mTOR pathway➡️cell proliferation, growth & survival
🔸Class I PIK3 proteins have catalytic subunit (p110)
🔸p110 contains 4 isoforms: α, β, γ, δ
🔸p110α mut (PIK3CA encoded)➡️ resistance to ET
📚pubmed.ncbi.nlm.nih.gov/31828441/
#BreastCancer
"Conducted by investigators at 11 cancer centres in India incld.Tata Memorial Centre in Mumbai over a 11-year period,it has shown that injecting 0.5% lidocaine, a common local anaesthesia agent, around the tumour increases cure rates." moneycontrol.com/news/trends/in…
"Conducted by investigators at 11 cancer centres in India incld.Tata Memorial Centre in Mumbai over a 11-year period,it has shown that injecting 0.5% lidocaine, a common local anaesthesia agent, around the tumour increases cure rates." moneycontrol.com/news/trends/in…
"it opens the window of peri-operative (around the time of surgery) intervention to modulate the environment of cancer ..to prevent its deleterious reaction to the act of surgery,” Rajendra Badwe, director, Tata Memorial Centre, who is the lead investigator of this study, said."
"“Evolving low-cost interventions for cancer has been a mission of Tata Memorial Centre and the Department of Atomic Energy for the benefit of Indian and global populations and this study is a major step towards Atmanirbhar Bharat,” he added"
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer 2/3 #TumorBoardTuesday
Thurs Case🎀
Take🏠:
✅HER2 LOW= IHC1+ OR IHC2+ w - ISH (67% HR+!)
✅T-DXd= after 1L chemo in HER2 low
✅Careful monitoring for ILD!
📚We captured @hoperugo & @LauraHuppert’s discussion in below:
twitter.com/i/events/15588…
twitter.com/i/events/15601…
Thurs Case🎀
Take🏠:
✅HER2 LOW= IHC1+ OR IHC2+ w - ISH (67% HR+!)
✅T-DXd= after 1L chemo in HER2 low
✅Careful monitoring for ILD!
📚We captured @hoperugo & @LauraHuppert’s discussion in below:
twitter.com/i/events/15588…
twitter.com/i/events/15601…
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert 2.75/3 #TumorBoardTuesday
Check out this graphic outlining the key role for ADCs in the tx of HER2 low #MBC after prior 1L chemo and endocrine therapy.
Hoping for even more changes in the near future w
DB-06!
Check out this graphic outlining the key role for ADCs in the tx of HER2 low #MBC after prior 1L chemo and endocrine therapy.
Hoping for even more changes in the near future w
DB-06!
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert @esinghimd @HemoncUcsf @UICHemOnc @Hopkins_HemOnc @TheFellowOnCall @jacobadashek 3/3 #TumorBoardTuesday
Special thanks to @hoperugo & @laura_huppert. It is a privilege to hear from experts who are re-defining tx for #breastcancer w next gen ADCs!
Join us on August 30 as @HosseinBorghaei discusses the latest in stage III #NSCLC!
Special thanks to @hoperugo & @laura_huppert. It is a privilege to hear from experts who are re-defining tx for #breastcancer w next gen ADCs!
Join us on August 30 as @HosseinBorghaei discusses the latest in stage III #NSCLC!
